Wei‐Hua Wu M.D.  Xiao‐Yi Xie M.D.  Lan Ma M.D.    Jing Lu M.D. 《Echocardiography (Mount Kisco, N.Y.)》2013,30(3):E64-E66

Perivalvular leaks are usually caused by suture interruption in prosthetic valves or infective endocarditis. Traumatic mitral annular dehiscence is a very uncommon event. We present a rare case of severe mitral regurgitation secondary to perivalvular abnormal communication in a 35‐year‐old man with a history of blunt chest trauma. He presented with symptoms of cough and chest tightness for 3 months. Preoperative two‐dimensional and real time three‐dimensional transesophageal echocardiography clearly showed the position and size of the perivalvular abnormal communication and the incident damage of the left ventricular wall. The patient finally underwent successful surgical repair.  相似文献   

    

Lisa C.A. D'Alessandro MD  Petra Werner DVM  PhD  Hongbo M. Xie PhD  Hakon Hakonarson MD  PhD  Peter S. White PhD  Elizabeth Goldmuntz MD 《Congenital heart disease》2014,9(1):83-86

  相似文献   

    

Hua Xiao  Minghui Liu  Lihua Tan  Xiangping Liao  Yajun Li  Jiesheng Gao  Fen Li  Xi Xie  Qinghai Peng  Ni Mao  Jing Tian  Jinfeng Du  Jinwei Chen 《International journal of rheumatic diseases》2014,17(7):767-775

  相似文献   

    

X. Xie  K.‐J. Luo  J. Wen  A. E. Bella  Y. Hu  F. Yang  J.‐H. Fu 《Diseases of the esophagus》2014,27(6):574-584

The effect of adjuvant chemotherapy on survival of patients with thoracic esophageal squamous cell carcinomas is still controversial, and the subgroup of patients who will most likely benefit from the adjuvant chemotherapy on long‐term survival has not yet been identified clearly. Studies published from 1995 to May 2012 were searched in Medline, Embase, PubMed, Cancerlit, the Cochrane Library, CNKI and major scientific meetings. Randomized controlled trials and nonrandomized studies comparing surgery plus adjuvant chemotherapy with surgery alone in patients with resectable thoracic esophageal squamous cell carcinomas were included. Eleven studies with a total of 2047 patients were identified, consisting of the adjuvant chemotherapy arm (n = 887) and surgery‐alone arm (n = 1160). There was not statistically significant benefit on 3‐year overall survival for adjuvant chemotherapy (risk ratio [RR] = 0.89, 95% confidence interval [CI], 0.72 to 1.09; P = 0.25). Adjuvant chemotherapy could significantly prolong the 1‐year disease‐free survival (DFS) (RR = 0.68, 95%CI, 0.51 to 0.89; P = 0.006), but not 3‐year DFS (RR = 0.97, 95%CI, 0.73 to 1.29; P = 0.84). Further analysis showed that patients with stage III‐IV diseases could benefit from adjuvant chemotherapy on 3‐year overall survival (RR = 0.43, 95%CI, 0.31 to 0.61; P = 0.00001), but not in the case of patients with stageI‐IIdiseases (RR = 1.12, 95%CI, 0.65 to 1.93; P = 0.68). Additionally, patients with positive lymph node could benefit on 5‐year DFS from adjuvant chemotherapy (RR = 0.79, 95%CI, 0.64 to 0.99; P = 0.04). The modality treatment with adjuvant chemotherapy for patients with squamous cell carcinoma of thoracic esophagus might be determined according to pathological stage or the status of lymph node metastasis.  相似文献   

    

Shifang Yang  Hongxu Wu  Junling Zhao  Xiaojie Wu  Jianping Zhao  Qin Ning  Yongjian Xu  Jungang Xie 《Respirology (Carlton, Vic.)》2014,19(8):1183-1190

  相似文献   

    

Yan Xie  Lawrence L. Hirschberger  Martha H. Stipanuk  Sayeepriyadarshini Anakk  David D. Moore  Mitsuhiro Watanabe  Susan Kennedy  Nicholas O. Davidson 《Hepatology research》2014,44(10):E218-E228

  相似文献   

    

L. Fu  Z. Huang  T. Song  S. He  D. Zeng  Z. Rao  L. Xie  Y. Song  L. Wang  T. Lin 《Transplant infectious disease》2014,16(5):760-766

  相似文献   

    

Tabitha N. Kung  Jessica Dennis  YiQing Ma  Gang Xie  Vivian Bykerk  Janet Pope  Carter Thorne  Edward Keystone  Katherine A. Siminovitch  France Gagnon 《Arthritis u0026amp; Rheumatology》2014,66(5):1111-1120

  相似文献   

    

Pai‐Yue Lu‐Fritts  Leah C. Kottyan  Judith A. James  Changchung Xie  Jeanette M. Buckholz  Susan M. Pinney  John B. Harley 《Arthritis u0026amp; Rheumatology》2014,66(11):3105-3112

  相似文献   

    

Chunya Bu  Lei Gao  Weidong Xie  Jainwei Zhang  Yuhong He  Guoping Cai  Keith R. McCrae 《Arthritis u0026amp; Rheumatology》2009,60(2):559-568

Objective

Regulation of the conversion of plasminogen to plasmin by tissue plasminogen activator (tPA) is critical in the control of fibrin deposition. While several plasminogen activators have been described, soluble plasma cofactors that stimulate fibrinolysis have not been characterized. The purpose of this study was to investigate the effects of β₂‐glycoprotein I (β₂GPI), an abundant plasma glycoprotein, on tPA‐mediated plasminogen activation.

Methods

The effect of β₂GPI on tPA‐mediated activation of plasminogen was assessed using amidolytic assays, a fibrin gel, and plasma clots. Binding of β₂GPI to tPA and plasminogen was determined in parallel. The effects of IgG fractions and anti‐β₂GPI antibodies from patients with antiphospholipid syndrome (APS) on tPA‐mediated plasminogen activation were also measured.

Results

Beta₂‐glycoprotein I stimulated tPA‐dependent plasminogen activation in the fluid phase and within a fibrin gel. The β₂GPI region responsible for stimulating tPA activity was shown to be at least partly contained within β₂GPI domain V. In addition, β₂GPI bound tPA with high affinity (K_d ∼20 nM), stimulated tPA amidolytic activity, and caused an overall 20‐fold increase in the catalytic efficiency (K_cat/K_m) of tPA‐mediated conversion of Glu‐plasminogen to plasmin. Moreover, depletion of β₂GPI from plasma led to diminished rates of clot lysis, with restoration of normal lysis rates following β₂GPI repletion. Stimulation of tPA‐mediated plasminogen activity by β₂GPI was inhibited by monoclonal anti‐β₂GPI antibodies as well as by anti‐β₂GPI antibodies from patients with APS.

Conclusion

These findings suggest that β₂GPI may be an endogenous regulator of fibrinolysis. Impairment of β₂GPI‐stimulated fibrinolysis by anti‐β₂GPI antibodies may contribute to the development of thrombosis in patients with APS.

  相似文献